Retrospective examination of pseudoprogression in IDH mutant gliomas.

Ethan A Wetzel,Matthew J Farrell,Blaine S C Eldred,Vicki Liu, Ishan Saha,Serendipity Zapanta Rinonos, Terry Prins,Tie Li,Minsong Cao,John Hegde,Tania Kaprealian,Negar Khanlou,Linda M Liau,Phioanh Leia Nghiemphu,Timothy Francis Cloughesy,Robert A Chong,Benjamin M Ellingson,Albert Lai

NEURO-ONCOLOGY ADVANCES（2023）

引用 0|浏览8

暂无评分

摘要

PsP patients represented 28% of CEnew patients and 16% of all patients; PsP patients demonstrated superior outcomes to TP patients, and equivalent survival to patients without CEnew. PsP persists for <1 year, occurs after treatment, and differs from TP based on time of onset and radiographic features. Poor outcomes after CEnew are driven by TP.

查看译文

关键词

contrast enhancement,glioma,IDH1,2,pseudoprogression,radiation necrosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要